<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8596">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00822237</url>
  </required_header>
  <id_info>
    <org_study_id>V210-057</org_study_id>
    <secondary_id>2009_510</secondary_id>
    <nct_id>NCT00822237</nct_id>
  </id_info>
  <brief_title>Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)</brief_title>
  <official_title>Safety, Tolerability, and Immunogenicity of VARIVAX (2007 Commercial VZV Bulk Process) Administered Concomitantly With M-M-R II in Healthy Children 12-to-23 Months of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety, tolerability, and immunogenicity of VARIVAX manufactured
      with the 2007 commercial Varicella-Zoster Virus (VZV) bulk process when concomitantly
      administered with M-M-R II in healthy children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This treatment has been approved for sale to the public.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process).</measure>
    <time_frame>6 weeks following first vaccination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of participants with varicella antibody titer â‰¥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) units/mL in participants with baseline varicella antibody titer &lt; 1.25 gpELISA units/mL.
Results for the VARIVAX (1999 Process) arm are not included in this table because the primary outcome measure is for the VARIVAX (2007 Process) arm only.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">598</enrollment>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>VARIVAX 2007 process + M-M-R II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VARIVAX 1999 process + M-M-R II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)</intervention_name>
    <description>VARIVAX (2007 process) in two 0.5 mL doses by injection ~6 weeks apart</description>
    <arm_group_label>VARIVAX 2007 process + M-M-R II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)</intervention_name>
    <description>VARIVAX (1999 process) in two 0.5 mL doses by injection ~6 weeks apart</description>
    <arm_group_label>VARIVAX 1999 process + M-M-R II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles, Mumps, and Rubella Virus Vaccine Live (MMR)</intervention_name>
    <description>M-M-R II in two 0.5 mL doses by injection ~6 weeks apart</description>
    <arm_group_label>VARIVAX 2007 process + M-M-R II</arm_group_label>
    <arm_group_label>VARIVAX 1999 process + M-M-R II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is in good health based on medical history

          -  Subject has no history of measles, mumps, rubella, chickenpox, or shingles

        Exclusion Criteria:

          -  Subject has previously received measles, mumps, rubella, and/or varicella vaccine
             either alone or in combination

          -  Subject has history of immune disorders

          -  Subject has been exposed to chickenpox/shingles, measles, mumps, rubella or varicella
             within 4 weeks of study start

          -  Subject has received an inactivated vaccine within 14 days of first dose of study
             vaccine

          -  Subject has received a live vaccine within 30 days of first dose of study vaccine

          -  Subject has received a blood transfusion or blood-derived products within 3 months of
             receiving study vaccine

          -  Subject has had a fever within 72 hours of study start
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 29, 2015</lastchanged_date>
  <firstreceived_date>January 9, 2009</firstreceived_date>
  <firstreceived_results_date>October 28, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>VARIVAX 2007 Process + M-M-R II</title>
          <description>VARIVAX (2007 process) in two 0.5 mL doses by injection ~6 weeks apart
M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) in two 0.5 mL doses by injection ~6 weeks apart</description>
        </group>
        <group group_id="P2">
          <title>VARIVAX 1999 Process + M-M-R II</title>
          <description>VARIVAX (1999 process) in two 0.5 mL doses by injection ~6 weeks apart
M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) in two 0.5 mL doses by injection ~6 weeks apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Dose 1 Vaccination</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="299">Number randomized</participants>
                <participants group_id="P2" count="299">Number randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="274"/>
                <participants group_id="P2" count="273"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Dose 2 Vaccination</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="274">Number who received second dose</participants>
                <participants group_id="P2" count="273">Number who received second dose</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="270"/>
                <participants group_id="P2" count="262"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VARIVAX 2007 Process + M-M-R II</title>
          <description>VARIVAX (2007 process) in two 0.5 mL doses by injection ~6 weeks apart
M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) in two 0.5 mL doses by injection ~6 weeks apart</description>
        </group>
        <group group_id="B2">
          <title>VARIVAX 1999 Process + M-M-R II</title>
          <description>VARIVAX (1999 process) in two 0.5 mL doses by injection ~6 weeks apart
M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) in two 0.5 mL doses by injection ~6 weeks apart</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="299"/>
                <measurement group_id="B2" value="299"/>
                <measurement group_id="B3" value="598"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13.0" spread="1.83"/>
                <measurement group_id="B2" value="13.0" spread="1.83"/>
                <measurement group_id="B3" value="13.0" spread="1.83"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="158"/>
                <measurement group_id="B2" value="138"/>
                <measurement group_id="B3" value="296"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="141"/>
                <measurement group_id="B2" value="161"/>
                <measurement group_id="B3" value="302"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process).</title>
        <description>Percent of participants with varicella antibody titer â‰¥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) units/mL in participants with baseline varicella antibody titer &lt; 1.25 gpELISA units/mL.
Results for the VARIVAX (1999 Process) arm are not included in this table because the primary outcome measure is for the VARIVAX (2007 Process) arm only.</description>
        <time_frame>6 weeks following first vaccination</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>VARIVAX 2007 Process + M-M-R II</title>
            <description>VARIVAX (2007 process) in two 0.5 mL doses by injection ~6 weeks apart
M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) in two 0.5 mL doses by injection ~6 weeks apart</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="246"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Participants Who Achieved Varicella Immunogenicity After a Single Dose of VARIVAX (2007 Process).</title>
            <description>Percent of participants with varicella antibody titer â‰¥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) units/mL in participants with baseline varicella antibody titer &lt; 1.25 gpELISA units/mL.
Results for the VARIVAX (1999 Process) arm are not included in this table because the primary outcome measure is for the VARIVAX (2007 Process) arm only.</description>
            <units>Percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Number of participants at risk for the 2007 process is the number who received the first dose.</desc>
      <group_list>
        <group group_id="E1">
          <title>VARIVAX 2007 Process + M-M-R II</title>
          <description>VARIVAX (2007 process) in two 0.5 mL doses by injection ~6 weeks apart
M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) in two 0.5 mL doses by
injection ~6 weeks apart</description>
        </group>
        <group group_id="E2">
          <title>VARIVAX 1999 Process + M-M-R II</title>
          <description>VARIVAX (1999 process) in two 0.5 mL doses by injection ~6 weeks apart
M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) in two 0.5 mL doses by
injection ~6 weeks apart</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="296"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="189" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="156" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="296"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="296"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="134" subjects_affected="67" subjects_at_risk="296"/>
                <counts group_id="E2" events="137" subjects_affected="64" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="205" subjects_affected="84" subjects_at_risk="296"/>
                <counts group_id="E2" events="167" subjects_affected="70" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="69" subjects_affected="32" subjects_at_risk="296"/>
                <counts group_id="E2" events="63" subjects_affected="35" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="34" subjects_affected="27" subjects_at_risk="296"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="110" subjects_affected="74" subjects_at_risk="296"/>
                <counts group_id="E2" events="92" subjects_affected="65" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="33" subjects_affected="31" subjects_at_risk="296"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="299"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="24" subjects_affected="20" subjects_at_risk="296"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="296"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="296"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="299"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
